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Abstract
Background:  Endoplasmic reticulum retention of misfolded cystic fibrosis transmembrane
conductance regulator (CFTR) mutants and their rapid degradation is the major cause of cystic
fibrosis (CF). An important goal is to understand the mechanism of how the misfolded proteins are
recognized, retained, and targeted for degradation.
Results: Using a web-based algorithm, PESTFind, we found a PEST sequence in the regulatory (R)
domain of CFTR. The PEST sequence is found in many short-lived eukaryotic proteins and plays a
role in their degradation. To determine its role in the stability and degradation of misprocessed
CFTR, we introduced a number of site-directed mutations into the PEST sequence in the cDNA of
∆F508 CFTR, the most prevalent misprocessed mutation found in CF patients. Analysis of these
mutants showed that the disruption of the PEST sequence plays a minor role in the degradation of
the CFTR mutants. Multiple mutations to the PEST sequence within the R domain of CFTR inhibit
maturation of CFTR and prevent the formation of a 100 kDa degradation product. The mutations,
however, do not improve the stability of the mutant ∆F508 CFTR.
Conclusion: These observations show that disruption of the structure of the R domain of CFTR
can inhibit maturation of the protein and that the predicted PEST sequence plays no significant role
in the degradation of CFTR.
Background
Mutations in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) gene cause cystic fibrosis (CF), the
most prevalent fatal recessive genetic disease in the Cauca-
sian population [1]. CFTR is a polytopic integral mem-
brane protein synthesized in the endoplasmic reticulum
(ER) and normally expressed on the apical surface of epi-
thelial cells where it functions as a phosphorylation-stim-
ulated and ATP-dependent chloride channel. The majority
of CF patients express processing defective CFTRs that fail
to mature to the cell surface; instead, the processing defec-
tive CFTRs are retained in the ER and are targeted for rapid
degradation [2,3].
The retention of processing defective CFTR is a response of
the ER quality control system to misfolded proteins,
which prevents the progression of misfolded or misassem-
bled membrane and secretory proteins into later compart-
ments of the secretory pathway [3]. During synthesis,
nascent CFTR polypeptide chains are translated from ER
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membrane-bound ribosomes and are inserted into the ER
membrane [3]. Various classes of chaperones associate
with the nascent polypeptide both in the lumen of the ER
and in the cytosol to aid in folding [4–7]. Upon proper
folding, the properly folded CFTR dissociate from the
chaperones and are packaged into transport vesicles for
export to a post-ER compartment in the secretory path-
way, the Golgi. Many of the missense mutations in CFTR
retard the folding process. This leads to prolonged associ-
ation of the nascent chains with the molecular chaperones
and prevents the nascent chains from exiting the ER
through the default secretory pathway. Instead, the mis-
folded polypeptides are retrotranslocated across the ER
membrane, into the cytosol, and targeted for degradation
by the ubiquitin-proteasome pathway [8].
Although much of the molecular mechanism of the ubiq-
uitin-proteasome system has now been elucidated (re-
viewed in [9]), the precise mechanism and determinants
of recognition of the misfolded polypeptides remain un-
clear [10]. As proposed by Chang et al. [11], the retention
of misfolded CFTR is most likely due to the exposure of
short sequence motifs specifically recognized by compo-
nents of the ER quality control system or vesicular trans-
port system; the mutations may cause localized
misfolding leading to global misfolding to expose or bury
motifs that signal for degradation, retention or exporta-
tion from the ER. Indeed, it has been shown that the re-
moval of multiple arginine-framed ER retention/retrieval
trafficking signals overcomes misprocessing of ∆F508
CFTR, the most prevalent processing defective CF muta-
tion [11].
Furthermore, attempts to promote maturation of the
processing defective mutants by shutting down the cy-
tosolic proteasomes via proteasome inhibitors have led to
the speculation of the existence of other systems responsi-
ble for the retention and degradation of these processing
defective CFTR [12]. Treatment of cells expressing wild-
type (WT) CFTR with MG-132, an inhibitor of the 26S
proteasome in the ubiquitin-proteasome pathway, leads
to inhibition of maturation of the CFTR polypeptide
[12,13]. The resulting maturation-hindered WT CFTR
polypeptide exhibit similar stability, structural, and func-
tional properties to misprocessed CFTR mutants such as
the prevalent ∆F508 CFTR [12,14].
PEST sequences are found in many rapidly degraded pro-
teins. These sequences have been suggested to serve as sig-
nals for proteolytic degradation. From a survey of the
amino acid sequences of 10 short-lived eukaryotic pro-
teins, Rogers et al. [15] found the proteins to contain one
or more regions rich in proline (P), glutamic acid (E), ser-
ine (S), and threonine (T). These regions are often flanked
by positively charged amino acids. They named these re-
gions PEST regions. Based on their observation, they de-
veloped an algorithm that would search for such regions
in a given protein sequence.
In the present study, we examine the role of a PEST se-
quence, found in CFTR, in the stability and degradation of
CFTR.
Results
PEST sequence of CFTR
The algorithm, PESTFind, searches for hydrophilic regions
of 12 or greater amino acids that contain at least one P
(proline), one E (glutamic acid) or D (aspartic acid), and
one S (serine) or T (threonine), flanked by K (lysine), R
(arginine), or H (histidine) residues. The algorithm as-
signs a score to each possible PEST sequence found. The
score ranges from -50 to +50, with a score above zero de-
noting a possible PEST region while a value greater than +
5 being of particular interest. Using the algorithm, PEST-
Find  [http://www.at.embnet.org/embnet/tools/bio/PES-
Tfind/], we found a highly conserved PEST region in the
regulatory domain of the CFTR protein (figure 1). The
CFTR PEST region (residues 716 – 734) scored + 6.91 and
had a hydrophobicity index of 32.63. Within the 19 resi-
dues PEST region, 8 are charged (i.e. 1 lysine, 1 arginine,
4 glutamic acid, and 2 aspartic acid), 4 polar (i.e. 1 threo-
nine, 1 serine, 1 glutamine, and 1 asparagine), and 7 non-
polar (i.e. 2 proline, 2 leucine, 1 methionine, 1 glycine,
and 1 isoleucine). The low hydrophobicity suggests the re-
gion may be surface accessible to proteases or for protein-
protein interaction with other proteins such as molecular
chaperones, trafficking proteins, or components of prote-
olytic systems.
Construction of PEST mutants
To examine whether the PEST sequence directly affects the
processing or proteolytic degradation of CFTR, various
CFTR PEST disrupting mutants were constructed into the
∆F508 CFTR cDNA using site-directed mutagenesis (table
1). An A52 epitope was also appended at the COOH-ter-
minus for detecting transfected CFTR as opposed to en-
dogenous CFTR. Table 1 lists the mutants with their
sequences and PEST scores as determined by the algo-
rithm, PESTFind. The mutants' PEST scores range from be-
ing poor PEST candidates (+4.07 for S728A and -26.19 for
poly-valine) to being invalid PEST candidates (i.e. no
score available). We were particularly interested in the
stretch of polar and PEST-significant region, residues 725
to 731. For that region, we made a poly-valine mutant
where we mutated the 6 consecutive polar/charged resi-
dues (725 – 730) to valine, a relatively small, neutral res-
idue. This minimized the hydrophobicity of the PEST
region and removed the majority of the significant PEST
residues; the proline residue 731 was not altered because
it may be important structurally (i.e. for formation of a β-BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/29
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turn). The E725K/E726K mutant was included to test if al-
teration of charges would affect the function of the PEST
sequence. Since serine and threonine are often implicated
in functional group modification such as phosphoryla-
tion, their role in the PEST sequence was examined. S728
and T717 were both altered to alanine, a small, neutral
residue; S728A has PEST score of +4.07. However, since
both S728A and T717A mutant have a high PEST score
(T717A mutant alone has PEST score of +3.87), we added
an additional E725K mutation to the T717A mutant just
to further disrupt the PEST sequence. The mutants were
also made in WT background. The WT-background con-
structs were included to ensure that the mutations them-
selves did not contribute to additional deleterious effects
on the protein.
Expression of PEST mutants
The cDNAs encoding the PEST mutants were transiently
transfected into COS-1 cells. The transfected cells were
harvested and lysed 3 days post-transfection, separated by
electrophoresis and subjected to Western blotting using a
mouse monoclonal antibody against the A52 tag [16,17]
attached at the COOH-terminus of the protein. The two
N-glycosylation sites on the putative extracellular loop 4
of CFTR (figure 1) enable us to determine the maturation
state of CFTR. During its synthesis in the ER, two carbohy-
drate moieties are covalently attached onto the two N-gly-
cosylation sites; this is the immature, core-glycosylated
CFTR. The carbohydrate moieties are modified only upon
the nascent polypeptide's maturation and progression
through the Golgi apparatus onto the cell surface; this is
the mature, fully-glycosylated CFTR. The modification of
the carbohydrate moieties lead to a shift in the protein's
apparent molecular mass: the core-glycosylated ER-resi-
dent CFTR has an apparent molecular mass of ~140 kDa
while the fully-glycosylated CFTR expressed on the cell
surface has an apparent molecular weight of ~170 kDa
[18]. While glycosylation of CFTR is not crucial in the
maturation CFTR, it serves as an indicator of CFTR's mat-
uration state [3].
As shown in figure 2A, the mutants had no apparent effect
on the maturation of CFTR with the exception of the poly-
valine mutant. The WT background constructs, except the
poly-valine mutant, all have similar levels of expression
and maturation as the WT CFTR. The poly-valine con-
struct in WT background is processing defective, similar to
the ∆F508 mutant. All of the ∆F508 background mutants
had no apparent effect on the maturation state of ∆F508
CFTR and are all immature. An over-exposure of the im-
munoblot (figure 2B), however, suggests removal of a
protease site by the poly-valine mutations. Since we do
not see any larger fragments (>100 kDa) in the poly-valine
mutants, it is also possible that the poly-valine mutations
introduced additional cleavage sites in the R domain. As
shown in figure 2B, the 100 kDa degradation product that
is present in ∆F508 is absent in the poly-valine constructs,
both of the WT and ∆F508 background. There is, however,
no improvement in maturation or in the level of expres-
sion.
Biogenesis of PEST mutants
It is possible that the effect of disruption of the PEST re-
gion may be too subtle to be detected from a simple ex-
pression blot. Effects of the disruption of the PEST region
may be only apparent by examining its stability in a pulse-
chase experiment.
To examine whether the disruption of the PEST sequence
affected the stability of the various mutants, the mutants'
biosynthetic maturation were examined kinetically in
Figure 1
Alignment of the PEST region of CFTR. The top line is
the human PEST sequence used in the study. A cross-species
alignment of the CFTR amino acid sequences from residues
716 to 734 of the human CFTR shows great conservation in
the region. Discrepancies with the human CFTR are noted in
italics. Significant PEST residues are noted with asteriks. The
PEST region is in the Regulatory (R) domain of CFTR. Partial
sequences were found using the PubMed  [http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed]. Acces-
sion number and references for each species are as follows:
Human (P13569; [1]), Rhesus (AAC14012; [56]), Macaque
(AAF80467; unpublished; direct submission), Baboon
(AAD46907; unpublished; direct submission), Rabbit
(Q00554; [57]), Sheep (Q00555; [58]), Bovine (P35071;
[58]), Rat (1901178A; unpublished; direct submission),
Mouse (P26361; [59]). The lower panel shows a model of
CFTR and location of the predicted PEST region in the R-
domain (R). The cylinders represent predicted transmem-
brane domains and the squares represent the nucleotide-
binding domains (NBD1 and NBD2).
NBD1
NBD2 PEST
R
***       *******  *
KTPLQM NGIEEDSDEP LER
Human 716 KTPLQM NGIEEDSDEP LER 734
Rhesus 714 KTPLQM NGIEEDSDEP LER 732
Macaque 716 KTPLQM NGIEEDSDEP LER 734
Baboon 716 KTPLQM NGIEEDSDEP LER 734
Rabbit 686 KTPLQM NGIEEDSDAS IER 704
Sheep 715 KTSLQM NGIDGASDEP LER 733
Bovine 715 KTSLQM NGIEGAADAP LER 733
Rat 714 KTPL-- -SIEGESDDL QER 729
Mouse 714 KTPL-- -CIDGESDDL QEK 729BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/29
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pulse-chase experiments (figure 3). COS-1 cells were tran-
siently transfected with the various constructs for 3 days
prior to the pulse-chase experiments. For the pulse-chase
experiment, the cells were starved for 30 minutes in sul-
fur-minus (S-) media depleted of methionine and
cysteine. The cells were then pulsed in S- media supple-
mented with radiolabeled methionine for 30 minutes.
The cells were then chased for 0, 2, 4, 6, 8, 12, and 24
hours in plain media. At each chase point, the cells were
harvested and frozen in plain media containing 10%
DMSO and stored in a -70°C freezer. After harvesting all
the time points, the cells were lysed, immunoprecipitated
with mouse anti-A52 antibody, separated by electro-
phoresis and detected by autoradiograph. As shown in fig-
ure 3A, all of the WT constructs, with the exception of the
poly-valine constructs, were still stable after 12 hours of
chase. All of the misprocessed constructs (∆F508 back-
ground and the poly-valine in WT background), however,
were completely degraded by the end of the 6 hours chase.
There was no apparent difference in the stability of the
constructs.
Global structural comparison of PEST mutants
To ensure that the disruption of the PEST region did not
cause significant structural differences in the protein, we
compared the global structures by examining their sensi-
tivity to trypsin digestion (figure 4). The trypsin-sensitivity
assay is based on the rationale that trypsin-sensitivity of
the various constructs depend on the exposure of trypsin-
sensitive sites. It has been previously established that nei-
ther the subcellular location nor the glycosylation state of
CFTR has a significant effect on its trypsin sensitivity [14].
Crude membranes were made from transiently transfected
cells. The membranes were treated with various concen-
trations of trypsin at room temperature for 5 minutes. The
reactions were stopped by the addition of lima bean
trypsin inhibitor. The samples were separated by SDS-
PAGE and subjected to Western blot with anti-A52 anti-
body. As shown in figure 4, mature CFTR were about 100–
1000 fold more resistant to trypsin than the immature ER-
resident CFTR. Thus, with the exception of the poly-valine
mutant with WT background, the PEST sequence-disrupt-
ing mutants did not have any apparent effect on the fold-
ing pattern of the CFTR protein.
Effect of MG-132 on PEST mutants
We then examined the effects of proteasome inhibitors on
the expression of these mutants to test our hypothesis that
the PEST region may act as a backup proteolytic system to
the ubiquitin-proteasome system; as the ubiquitin-protea-
some system has been shown to be the prevalent proteo-
lytic system of misprocessed CFTR, it is possible for it to
overshadow whatever proteolytic effects of the PEST re-
gion may possess. COS-1 cells transiently transfected with
various cDNA of the PEST constructs were treated with 2
µM of MG-132. MG-132 is a potent peptide aldehyde in-
hibitor designed to enter mammalian cells to inhibit the
ubiquitin-proteasome pathway [19,20]. As shown in fig-
ure 5, MG-132 blocks the maturation of WT CFTR and
WT-background mutants. Inhibition of maturation by
MG-132 has also been observed with P-glycoprotein [21].
The level of expression, however, remains similar to that
of the immature CFTR in untreated cells. With the ∆F508
CFTR, poly-valine mutant and the other ∆F508-
backgound mutants, however, there was lower expression
in the presence of MG-132.
Discussion
Increasing the stability and promoting the maturation of
misprocessed CFTR mutants has been a key interest in CF
research. So far, not much is known about the actual
mechanism of how these misprocessed CFTR are retained
in the ER and targeted for degradation. Many lines of evi-
dence have suggested the ER-associated degradation
(ERAD) pathway, which includes the ubiquitin-protease
pathway, as the dominant pathway for the disposal of
misfolded CFTR in mammalian cells [4,22,23]. Misfolded
or misassembled proteins, such as processing defective
∆F508 mutant CFTR, are recognized and retained in the
ER by the quality control system in the ER; although the
exact mechanism for recognition is yet to be elucidated,
evidence indicate that the prolonged association with mo-
Table 1: Mutations introduced into the predicted PEST sequence of CFTR
Mutant Sequence PEST Score
Wild-type (WT) 716 – KTPLQMNGIEEDSDEPLER – 734 +6.91
Poly-Valine 716 – KTPLQMNGIVVVVVVPLER – 734 -26.19
E725K/E726K 716 – KTPLQMNGIKKDSDEPLER – 734 N/A
S728A 716 – KTPLQMNGIEEDADEPLER – 734 +4.07
T717A/E725K 716 – KAPLQMNGIKEDSDEPLER – 734 N/A
* Residues in bold are the mutations introduced.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/29
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lecular chaperones may play a role in the retention of
CFTR [5,24]. Ubiquitination, the covalent attachment of
ubiquitin to a lysyl ∈-amino group of the polypeptide, is
necessary for degradation by the 26S proteasome [25].
Ubiquitin is a highly conserved polypeptide of 76 amino
acids. CFTR may be both co- and post-translationally
ubiquitinated in cell-free systems [26,27]. Although the
precise mechanism is still unclear, ubiquitination and ER
retention eventually lead to the retrotranslocation of the
misfolded protein back into the cytosol via the sec61p
translocon [27,28]. The misfolded protein is then targeted
for degradation by the 26S proteasome [25].
There are still many questions about the ERAD pathway
and the maturation process of WT CFTR: 1) Although the
mechanism for the ubiquitination reaction is well under-
stood [10], the recognition determinants for ubiquitina-
tion are still unknown. 2) How does the ERAD pathway
recognize the misfolded protein? 3) Although both WT
and ∆F508 CFTR are ubiquitinated, how is some WT CFTR
still able to progress onto the post-ER compartments of
the secretory pathway? In a recent report, CHIP, an Hsc70
co-chaperone was actually found to target immature CFTR
for proteasomal degradation [5]. It is likely that there are
other chaperones that function in a similar manner. So,
what are the selective molecular determinants for chaper-
ones such as the CHIP to target only immature CFTR but
not the mature form? Furthermore, it is the general con-
sensus that there must be a number of criteria for exiting
the ER and progressing through the secretory pathway for
expression on the cell surface. Peptide motifs and signals
may be exposed or buried depending on the folding state
of the protein, thus providing the cell with a means of
quality control. The perfect example is the four arginine-
framed trafficking signals in CFTR discovered by Chang et
al. [11]. The arginine-framed trafficking signal, however,
may just be one of the many types of signals.
There are a number of peptide motifs identified in rapidly
degraded proteins that target proteins for rapid degrada-
tion: PEST regions [29], lysosome-targeting KFERQ motifs
[30], and the cyclin destruction box responsible for eu-
karyotic cell cycle [31]. The PEST region is of particular in-
terest to us because it has been found in many rapidly-
degraded proteins and shown to contribute to their degra-
dation [15,29,32]. Although the presence of PEST motifs
does not necessarily lead to constitutive degradation of
the protein, there were a number of reasons why we
thought it was worth investigating. Aside from its proteo-
lytic roles, PEST motifs have also been found to be in-
Figure 2
Expression of PEST Mutants in COS-1 Cells. A) COS-1 cells were transiently transfected with cDNA encoding the vari-
ous PEST mutants in both WT and ∆F508 background. Whole cell extracts were subjected to SDS-PAGE and immunoblot
analysis (monoclonal antibody against the A52 tag) as described in 'Materials and Methods'. B) An over-exposure of the immu-
noblot showed the disappearance of the CFTR 100 kDa degradation product with the introduction of the poly-valine con-
structs.
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volved in protein-protein interactions: direct interaction
with ubc9 [33] and ligand recognition [34,35]. The PEST
region of CFTR lies within its R domain, which is not
present in its processing efficient sister protein, P-glyco-
protein [36]. Thus, apart from a potential proteolytic site,
the PEST region in CFTR also has the potential to interact
with ubiquitination proteins, other proteases, or molecu-
lar chaperones. We were interested in seeing if it affects the
maturation, folding, and stability of the CFTR protein. To
this end, a number of constructs were made via site-direct-
ed mutagenesis aiming to disrupt the PEST region and ex-
amine the stability and folding pattern of the constructs.
To narrow the scope of our study in this paper, we tested
the PEST sequence's potential role as a proteolytic site in
misprocessed CFTR. A number of mutants were made to
disrupt the PEST sequence in the processing defective
∆F508 CFTR mutant in an attempt to rescue it. The mu-
tants' stability and maturation was examined via pulse-
chase experiments and their global structure compared by
testing their trypsin sensitivity. Overall, it was found that
perturbation to the PEST sequence (residues 716 – 734) of
CFTR made no apparent improvement on the stability of
∆F508 CFTR.
In our survey of PEST-disrupting mutants, we included the
WT-background mutants as well as the processing defec-
tive ∆F508-background mutants as a control to ensure the
missense mutations themselves did not cause other dele-
terious effect on the protein. The misprocessed poly-va-
line construct proves this precaution to be necessary.
The observation that poly-valine caused defective process-
ing came as a surprise since the R domain has been previ-
ously shown to be predominantly random coil [37].
Although the boundaries of the R domain are still not pre-
cisely defined, the R domain extends approximately from
residues 634–708 at the NH2-terminus to approximately
835 at the COOH-terminus [37–39]. Various studies have
shown that the deletion of the R-domain yields cell sur-
face expressing, functional CFTR [40–45]. Furthermore, of
the 19 disease-associated mutations in the R-domain ex-
amined by Vankeerberghen et al. [46], none of the clinical
missense mutations studied within the boundaries of the
R domain (residues 634 – 835) was processing defective.
Thus, it appeared that the R-domain did not contain sig-
nificant structural information.
However, the fact that the poly valine mutant used in our
study leads to such dramatic disturbance as to cause the
Figure 3
Biosynthetic Maturation of CFTR PEST Mutants. A) Pulse-chase radiograph for non-processing defective constructs:
WT, WT/E725K/E726K, and WT/T717A/E725K; results for WT/S728A not shown, but is similar to that of WT. B) Pulse-chase
radiograph for processing defective constructs: ∆F508,  ∆F508/poly-valine,  ∆F508/E725K/E726K, and ∆F508/T717/E725K;
results for WT/Poly-valine and ∆F508/S728A not shown but they show similar results as ∆F508. Pulse-chase experiments and
immunoprecipitation were performed as described in the "Materials and Methods" section.
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mutant protein to not mature suggests otherwise. Using a
web-based secondary structure prediction program,
NNPREDICT  [http://www.cmpharm.ucsf.edu/~nomi/
nnpredict], the PEST region and surrounding regions (res-
idues 712–737) contain turning elements, with 3 helical
elements. With the PEST region's low hydrophobicity, the
region is likely to be surface-accessible. The poly-valine
mutant, however, introduces beta strand elements in the
middle of the turning elements. This could have led to dis-
ruption of a turn, and thus disrupting global structure. If
the primary sequence around the PEST region does indeed
carry structural information, perturbation of the PEST re-
gion by the other mutations might have also led to struc-
tural change and the trypsin assay might not be sensitive
enough to detect them. These structural changes might
have led to exposure of other proteolytic sites to counter
the loss of proteolytic effect caused by alternation of the
PEST sequence, hence, no apparent improvement in sta-
bility. An alternative test of structural change would be to
find cysteine cross-linking pairs in CFTR and test if they
still exist in the mutants [47]. This would act as an addi-
tional structural check of the mutants.
The PEST region may still interact with other proteins. The
c-Myb transcription factor is a highly regulated nuclear
phosphoprotein involved in the regulation of prolifera-
tion, differentiation, and apoptosis of immature hemat-
opoietic cells. Its activity and proteolytic stability are, in
part, regulated by the ubiquitin-proteasome system. c-
Myb contains a PEST motif in its regulatory domain at its
COOH-terminus. The PEST motif was found to directly
interact with Ubc9. Ubc9 covalently attaches SUMO-1
protein, an ubiquitin-like protein, onto the lysyl residue
near the PEST motif [33]. Similarly, Ubc9 interacts with
Figure 4
Trypsin Sensitivity of CFTR PEST Mutants. Membranes were prepared from COS-1 cells transiently transfected with
the cDNA of the various constructs. The membranes were treated with various concentrations (0–1000 µg/ml) of TPCK-
treated trypsin. The reactions were stopped by the addition of lima bean trypsin inhibitor. Equivalent amounts of protein were
subjected to immunoblot analysis (monoclonal antibody against the A52 tag).
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the PEST region of another nuclear SUMO-1 target pro-
tein, HIPK2 [48]. Deletion of the PEST motif, however,
does not increase the stability of the protein, suggesting
other additional factors may contribute to the proteolytic
stability of the proteins.
There are a number of lysyl residues to the NH2-terminus
of the PEST region and may act as potential candidates for
ubiquitination. If CFTR's PEST motif also acts as a binding
site for ubiquitin-conjugating enzymes like Ubc9 was for
SUMO-1, that would explain why no difference was ob-
served in the treatment of proteasome inhibitors between
the WT and PEST mutants; the PEST motif would be part
of the ubiquitin-proteasome pathway and not a separate
proteolytic pathway. A potential candidate may be the
Ubc6, an ER-resident ubiquitin-conjugating enzyme. In a
recent report, mutation in Ubc6 was able increase the sta-
bility of ∆F508 CFTR by 2 fold [22].
Conclusions
Our results suggest the PEST region in the R domain of
CFTR plays no discernible role in degradation of CFTR
and that there may be structural information encoded in
the R domain as mutations in the region may lead to mis-
processing of the protein. The issue of whether CFTR's
PEST motif can act as a recognition site, for other proteins,
however, has not yet been addressed. As retention and
degradation of misfolded CFTR is likely a collective work
by many protein complexes, a survey of components of
the proteolytic systems, molecular chaperones may yield
more insight into the whether PEST motif plays a role in
the degradation of CFTR.
Methods
Construction of mutants
The CFTR point mutations were constructed and inserted
into the mammalian expression vectors pMT21 as previ-
ously described [18,49]. The full-length cDNA of all con-
structs were modified to encode the epitope for
monoclonal antibody A52 [50] and 6 histidine residues at
the C-terminus [51]. The sequence at the COOH terminus
that would normally end DTRL then became DTRRAIS-
LISNSCSPEFDDLPLAEQREACRRGD (His)6PRQ. Brief-
ly, a BssHII restriction site was constructed at amino acid
residue 1480 via site-directed mutagenesis using the DNA
oligomer AAGATACAAGGCGCGCGAGAGCAGCAT to al-
ter the Leu and stop codon to Arg and Ala. The DNA frag-
ment encoding the A52 tag with a 5' BssHII site was then
ligated to the 3' of the cftr gene.
Expression of wild-type CFTR and mutants
Subconfluent COS-1 cells were transfected with the cDNA
constructs with 1 µg/ml of the various vector constructs
using a calcium phosphate precipitation method adapted
from Chen and Okayama [52]. The media was replaced
with plain media at 20 hours post-transfection. The cells
were harvested after another 48 hours.
Isolation of microsomal membrane vesicles for trypsin di-
gestion
The crude membranes were prepared in the same manner
as optimized by Loo and Clarke [53] for trypsin digestion
assays. Briefly, for each CFTR construct, 20 (100 mm) tis-
sue culture plates of transfected COS-1 cells were harvest-
ed and washed with PBS (phosphate-buffered saline). The
cell pellets were subsequently resuspended in 3 ml of low
ionic strength buffer (10 mM Tris-HCl, pH 7.5, 0.5 mM
MgCl2). After incubating on ice for 20 min., the samples
were homogenized using 40 strokes in a loose fitting
Dounce homogenizer, followed by 20 strokes after addi-
tion of 3 ml of sucrose buffer (10 mM Tris-HCl, pH 7.5,
500 mM sucrose, 0.3 M KCl). The cell debris was removed
by centrifugation at 3000 × g for 7 min. at 4°C. The micro-
somes were collected from the supernatant by centrifuga-
Figure 5
Treatment with Proteasome Inhibitors. Transiently
transfected COS-1 cells were treated with (+) or without (-)
2 µM MG-132. The cells were subsequently lysed and sub-
jected to immunoblot analysis (monoclonal antibody against
the A52 tag).
WT/∆F508 Mature
Immature
Poly-Valine Mature
Immature
S728A Mature
Immature
E725K/E726K Mature
Immature
T717A/E725K Mature
Immature
- + - +
WT
CFTR
∆ ∆ ∆ ∆F508
CFTR
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tion at 44,000 × g for 45 min. at 4°C and resuspended
with 300 µl of TBS (Tris-buffered saline; 10 mM Tris-HCl,
pH 7.5, 150 mM NaCl). The membrane vesicles were im-
mediately used for the trypsin digestion.
Trypsin digestion
As described previously [54], membrane vesicles from var-
ious constructs were treated with different concentrations
of TPCK-trypsin (L-1-tosyl-amido-2-phenylethylchlo-
romethyl ketone-treated trypsin; Sigma, 12,000 BAEE
units per mg) at room temperature for 5 min.; the final
concentrations of TPCK-trypsin were: 0, 0.1, 1, 10, 100,
and 1000 µg/ml. The reactions were stopped by the addi-
tion of 2 mg/ml lima bean trypsin inhibitor (Worthing-
ton). The vesicles were solubilized with 2X sample buffer
(3% SDS, 5% β-mercaptoethanol, 10% glycerol, 62.5 mM
Tris-HCl, pH 6.8). The samples were then subjected to
SDS-PAGE and immunoblot analysis using mouse A52
monoclonal antibody as the primary antibody and a
horseradish peroxidase labeled goat anti-mouse antibody
as the secondary antibody. The signals were detected by
chemiluminescence (enhanced chemiluminescence,
Pierce).
Pulse chase
Using methods adapted from Loo and Clarke [55], COS-
1 cells expressing various CFTR constructs were radiola-
beled and biogenesis of CFTR was followed. For each
CFTR construct, 8 (100 mm) tissue culture plates of sub-
confluent COS-1 cells were transfected. At 24 hours post-
transfection, the transfection media were replaced with
plain media. At 72 hours post-transfection, the cells were
starved for 40 minutes in Dulbecco's Modified Eagle Me-
dium (DMEM) without L-methionine or L-cystine (Invit-
rogene Life Technologies). After aspirating the sulfur-
deficient medium, the cells were labeled for 30 minutes in
sulfur-deficient DMEM supplemented with 40 µCi/ml
[35S] L-methionine and [35S] L-cystine (ICN Radiochemi-
cals). The samples were then chased with plain media.
One (100 mm) tissue culture plate from each construct
was harvested at various chase time point, resuspended in
10% dimethylsulfoxide-containing media, and frozen in -
70°C freezer.
Immunoprecipitation of CFTR
After thawing, each harvested pulse-chase sample was
washed in PBS and subsequently resuspended in 100 µl
PBS. The samples were then lysed in 1 mL buffer I (25 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 % (v/v) Triton X-100,
0.5 % (w/v) deoxycholic acid, 1 mM EDTA, pH 8.0) with
protease inhibitors (50 µg/ml AEBSF, 10 µg/ml aprotinin,
25 µg/ml benzamidine, 1 µg/ml E64, and 0.5 µg/ml leu-
peptin). After removing the cell debris via centrifugation
at 16,000 × g for 5 minutes, the supernatants were incu-
bated with 11 µg of monoclonal A52 antibody at 4°C for
1.5 hour. 50 µl 50 % (v/v) slurry of Protein A beads in TBS
(Protein A sephrose 4 Fast Flow; Amersham Pharmacia)
was added to each sample and incubated at 4°C for 2
hours. The Protein A beads were then washed 3 times with
buffer I. The CFTR proteins were then eluted with 50 µl 2X
Sample Buffer with 2% β-mercaptoethanol. The samples
were then subjected to separation on 6% SDS-acrylamide
gel via SDS-PAGE. The gels were fixed in 10% acetic acid
for 30 minutes and the 35S signal amplified in Amplify so-
lution (Amersham Pharmacia) for 30 minutes. The gels
were then dried and exposed to X-OMAT AR film (Kodak)
for 12 hours – 1 week @ -70°C.
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